(P26-018-25) Evaluation of Reducose® in C. elegans: Exploring Multifaceted Health Benefits Using an AI-Assisted Microfluidic Platform

Objectives: This study aims to identify novel benefits and mechanisms of action for Reducose®, a proprietary aqueous mulberry leaf extract. Numerous clinical studies demonstrate the utility of Reducose in reducing postprandial glucose and insulin responses via competitive inhibition of α-glucosidases in the small intestine. Using the Caenorhabditis elegans (C. elegans) model, we will investigate both 1% and 5% versions of Reducose to determine its potential benefits across various health domains, including brain health, muscle performance, gut health, stress resilience, healthy aging, and overall metabolism.

Methods: Preclinical studies with Reducose will be conducted using two discovery pipelines powered by NemaLife’s AI-assisted organism-on-a-chip platform. The Discovery Flywheel™ will be used to simultaneously assess six efficacy endpoints relevant for longevity, cognitive health, muscle health, gut health, stress resilience and metabolic health. Complementing this, the BioSeq™ pipeline utilizing high throughput RNA-seq will be used to identify differentially expressed genes in C. elegans and their human orthologs, potentially revealing mechanistic pathways activated by Reducose in vivo. Both the Discovery Flywheel and BioSeq studies will be conducted with nematodes exposed to 1% and 5% Reducose in their growth medium.

Results: N/A

Conclusions: This research aims to provide valuable insights into the putative effects of Reducose. By leveraging the organism-on-a-chip platform, we expect to uncover potential benefits of Reducose beyond its known effects on glucose metabolism. The results from this study will inform future research directions and may support additional clinical trials with Reducose for various health applications, including metabolic health, neuroprotection, and healthy aging.

Funding Sources: Phynova Group Ltd